Sanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide - Seite 2

 

 

Contacts:

Media Relations Mai Tran Tel.: + (33) 1 53 77 46 46 [e-mail]	Investor Relations George Grofik Tel.: + (33) 1 53 77 45 45 [e-mail]
Global Diabetes Communications Philip McNamara Tel.: [phone] [e-mail]

Press release (PDF)

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

HUG#2036140